¥1,742.50
0.37%
Tokyo, Sep 25, 03:15 pm JST. Closed.
ISIN
JP3336000009
Symbol
4536

Santen Pharmaceutical Target price 2026 - Analyst rating & recommendation

Santen Pharmaceutical Classifications & Recommendation

Buy
69%
Hold
31%

Santen Pharmaceutical Price Target

Target Price ¥2,371.50
Price ¥1,748.50
Potential
Number of Estimates 10
10 Analysts have issued a price target Santen Pharmaceutical 2027 . The average Santen Pharmaceutical target price is ¥2,371.50. This is higher than the current stock price. The highest price target is
¥2,940.00 68.14%
register free of charge
, the lowest is
¥1,919.00 9.75%
register free of charge
.
A rating was issued by 13 analysts: 9 Analysts recommend Santen Pharmaceutical to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Santen Pharmaceutical stock has an average upside potential 2027 of . Most analysts recommend the Santen Pharmaceutical stock at Purchase.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Billion ¥ 291.62 307.12
2.79% 5.31%
EBITDA Margin 20.58% 22.61%
0.38% 9.84%
Net Margin 12.81% 13.01%
6.06% 1.53%

10 Analysts have issued a sales forecast Santen Pharmaceutical 2027 . The average Santen Pharmaceutical sales estimate is

¥307b
unlock
. This is
5.23% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥329b 12.61%
unlock
, the lowest is
¥287b 1.81%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 ¥292b 2.79%
2027
¥307b 5.31%
unlock
2028
¥318b 3.40%
unlock
2029
¥330b 3.92%
unlock

10 Analysts have issued an Santen Pharmaceutical EBITDA forecast 2027. The average Santen Pharmaceutical EBITDA estimate is

¥69.5b
unlock
. This is
21.35% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
¥77.9b 36.07%
unlock
, the lowest is
¥61.8b 8.04%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 ¥60.0b 3.16%
2027
¥69.5b 15.70%
unlock
2028
¥74.9b 7.77%
unlock
2029
¥80.6b 7.73%
unlock

EBITDA Margin

2026 20.58% 0.38%
2027
22.61% 9.84%
unlock
2028
23.57% 4.25%
unlock
2029
24.43% 3.65%
unlock

10 Santen Pharmaceutical Analysts have issued a net profit forecast 2027. The average Santen Pharmaceutical net profit estimate is

¥40.0b
unlock
. This is
3.29% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥47.5b 22.66%
unlock
, the lowest is
¥32.0b 17.25%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 ¥37.4b 3.10%
2027
¥40.0b 6.93%
unlock
2028
¥43.8b 9.54%
unlock
2029
¥48.0b 9.58%
unlock

Net Margin

2026 12.81% 6.06%
2027
13.01% 1.53%
unlock
2028
13.78% 5.92%
unlock
2029
14.53% 5.44%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share ¥ 114.06 124.41
10.04% 9.07%
P/E 14.05
EV/Sales 1.75

10 Analysts have issued a Santen Pharmaceutical forecast for earnings per share. The average Santen Pharmaceutical EPS is

¥124.41
unlock
. This is
3.35% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
¥147.73 22.72%
unlock
, the lowest is
¥99.67 17.20%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 ¥114.06 10.04%
2027
¥124.41 9.07%
unlock
2028
¥136.27 9.53%
unlock
2029
¥149.33 9.58%
unlock

P/E ratio

Current 14.52 18.25%
2027
14.05 3.27%
unlock
2028
12.83 8.68%
unlock
2029
11.71 8.73%
unlock

Based on analysts' sales estimates for 2027, the Santen Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.85 1.09%
2027
1.75 5.18%
unlock
2028
1.70 3.29%
unlock
2029
1.63 3.78%
unlock

P/S ratio

Current 1.91 0.15%
2027
1.82 4.97%
unlock
2028
1.76 3.29%
unlock
2029
1.69 3.78%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today